Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non–Small-Cell Lung Cancer: Case Series

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00476 JCO Precision Oncology no. 7 (2023) e2200476. Published online February 21, 2023. PMID: 36809053 Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non–Small-Cell Lung Cancer: Case Series Ashish Gupta , MBBS1xAshish GuptaSearch for articles by this author; Karan Jatwani, MBBS1xKaran JatwaniSearch for articles by this author; Kush Gupta, MBBS2xKush GuptaSearch for articles by this author; Jingxin Qiu, MD, PhD3xJingxin QiuSearch for articles by this author; and Grace K. Dy , MD1xGrace K. DySearch for articles by this author Show More 1Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY2Department of Medicine, University of Massachusetts Medical School—Baystate, Springfield, MA3Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://doi.org/10.1200/PO.22.00476 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Ashish Gupta, Karan Jatwani, Grace K. DyProvision of study materials or patients: Ashish Gupta, Karan Jatwani, Grace K. DyCollection and assembly of data: All authorsData analysis and interpretation: Ashish Gupta, Karan Jatwani, Kush Gupta, Grace K. DyManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Grace K. DyConsulting or Advisory Role: AstraZeneca, Mirati Therapeutics, Lilly, Amgen, RegeneronResearch Funding: Bristol-Myers Squibb (Inst), Tesaro (Inst), AMGEN (Inst), AstraZeneca (Inst), Mirati Therapeutics (Inst), Lilly (Inst)No other potential conflicts of interest were reported.